CivaTech Oncology

Executive Summary

CivaTech Oncology is a privately held medical device company focused on polymer-based low-dose rate (LDR) brachytherapy. Its flagship products, CivaString® and CivaSheet®, offer a non-metallic, directional alternative to traditional radioactive seeds, enabling localized cancer treatment with reduced trauma and simplified workflows. The company differentiates itself by eliminating the need for metal shielding and providing customizable radiation dosimetry. Based in Durham, North Carolina, CivaTech targets solid tumors in sites such as the prostate, gynecological, and head-and-neck cancers. While the company has established a niche in the brachytherapy market, its private status limits public financial visibility. However, the growing demand for minimally invasive cancer therapies and the advantages of its polymer technology position CivaTech for potential expansion through new clinical indications and strategic partnerships.

Upcoming Catalysts (preview)

• Q2 2027Expanded FDA Clearance for CivaSheet in Additional Tumor Sites70% success
• Q4 2026Publication of Favorable Clinical Outcomes in Peer-Reviewed Journal65% success
• Q1 2027Strategic Distribution or Licensing Agreement with Larger Oncology Firm40% success